GLP-1 RAs have also shown efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD) and are now recommended as a first-line antidiabetic treatment for patients with metabolic dysfunction-associated steatohepatitis (MASH) and diabetes [82]. The gene discussed is GLP1R; the disease is diabetes mellitus.